Brief: Vyne Therapeutics Provides Program Update On Oral BET Inhibitor VYN202

YARROW BIOSCIENCE

02/07/2025 13:14

July 2 (Reuters) - Vyne Therapeutics Inc VYNE.O:

VYNE THERAPEUTICS PROVIDES PROGRAM UPDATE ON ORAL BET INHIBITOR VYN202

VYNE THERAPEUTICS INC - FDA LIFTS CLINICAL HOLD FOR FEMALE PATIENTS ON 0.25 MG AND 0.5 MG DOSES

VYNE THERAPEUTICS INC - 12-WEEK TOXICOLOGY STUDY IN DOGS REQUIRED TO RESUME TRIAL IN MALES

VYNE THERAPEUTICS INC - TO STOP ENROLLING PATIENTS IN PHASE 1B PSORIASIS STUDY

VYNE THERAPEUTICS INC - UNBLINDS CLINICAL DATA FROM ENROLLED SUBJECTS IN STUDY

Source text: ID:nGNX4z5k55

Further company coverage: VYNE.O

 ((Reuters.Briefs@thomsonreuters.com;))